Articles related to BIOMARKERS

A 9-member Delphi panel just issued 65 implementation recommendations for anti-amyloid mAbs in private practice. Here’s what counts as practice-shaping and what’s still consensus opinion.

Persistent EBV antibody elevations distinguished MS from MOGAD and NMOSD when tracked over time in a large multicenter cohort.

The new method, called MethylScan, works by analyzing cell-free DNA (cfDNA), which carries molecular signals that reflect what is happening throughout the body.

“By comparing current standard-of-care treatments with a potential novel therapy in refractory mCRC, this review underscores existing gaps and highlights future research priorities while awaiting randomized data.” – Elisabetta Bengala, MD, Regina Elena National Cancer Institute, Rome, Italy

The study authors concluded, “These findings further our understanding of shared and distinct neural mechanisms underlying mood disorders and assist in differential diagnosis, thereby guiding more accurate treatment strategies.”

The 2024 McDonald criteria continue to emphasize the importance of considering differential diagnoses, including reevaluating the diagnosis periodically over the disease course, even after a diagnosis of MS has been made.